Viatris Inc Ord Shs Stock Price, News & Analysis

Viatris hosted an event through its EmpoWer employee resource group, featuring women leaders sharing experiences of overcoming gender bias in their careers. Yoo-Kyung (Karen) Choi, Head of Compliance for Japan, Australia, New Zealand and South Korea, recalled a childhood incident that motivated her to excel. Rania Gabr, Head of Marketing and Business Excellence for Japan, Australia, New Zealand and Emerging Markets, discussed facing gender-based obstacles in her career progression. Both emphasized the importance of resilience and hard work in achieving success. The event highlighted the global nature of gender inequality and the ongoing efforts to promote women's empowerment in the workplace.

Viatris' 2023 Sustainability Report highlights the company's commitment to patient advocacy and empowerment. The report outlines various collaborations and initiatives undertaken in 2023, including:

• Partnering with Allergy & Anaphylaxis Australia for awareness campaigns and patient education
• Sponsoring the COPD Foundation's Lace up for Lungs campaign in the U.S.
• Supporting the Cystic Fibrosis Foundation and Boomer Esiason Foundation
• Collaborating with multiple sclerosis advocacy associations
• Creating the MyHealthMyLife website for disease awareness
• Partnering with the Active Citizen Network to strengthen patients' voices in health policies

These efforts aim to provide patients and caregivers with access to information, raise awareness, and empower them to actively participate in their healthcare journey.

Viatris Inc. (NASDAQ: VTRS) announced the expiration of cash tender offers for its 1.650% Senior Notes due 2025 and Mylan Inc.'s 2.125% Senior Notes due 2025. $431,981,000 of Viatris Notes and €208,100,000 of Mylan Notes were validly tendered. Holders are expected to receive $977.66 per $1,000 of Viatris Notes and €994.12 per €1,000 of Mylan Notes, plus accrued interest. The settlement date is set for September 16, 2024. Viatris and Mylan intend to satisfy and discharge or redeem any remaining notes. The purchase will be funded with cash on hand. Barclays, Citigroup, and J.P. Morgan acted as lead dealer managers for the tender offers.

Viatris Inc. (NASDAQ: VTRS) has announced the pricing terms for its previously announced cash tender offers for two series of senior notes. The offers include:

• Any and all of the outstanding 1.650% Senior Notes due 2025 issued by Viatris
• Any and all of the outstanding 2.125% Senior Notes due 2025 issued by Mylan Inc.

The tender offers are set to expire at 5:00 p.m., New York City time, on September 10, 2024. The Total Consideration for each $1,000 principal amount of Viatris Notes is $977.66, while for each €1,000 principal amount of Mylan Notes, it's €994.12. These prices include accrued and unpaid interest up to, but not including, the expected settlement date of September 16, 2024.

Viatris, a global pharmaceutical company, released its 2023 Sustainability Report highlighting efforts to break down systemic barriers to medicine access through policy engagement. As a member of ~160 trade associations, Viatris leverages its global experience and expertise to support policymakers in developing policies that advance access to quality medicines.

Key initiatives in 2023 included:

• Advancing regulatory harmonization through participation in International Council on Harmonization (ICH) working groups
• Supporting the UK's Windsor Framework to protect post-Brexit medicine access
• Partnering with the Center for Research on Complex Generics in the U.S.
• Assessing localization policies' impact on medicine access
• Engaging in the European Pharmaceutical Legislation revision
• Supporting studies on healthcare investment and innovative financing for Universal Health Coverage

Viatris' global policy priorities focus on advancing access to quality medicines, strengthening resilient global supply, and building future access across diverse therapeutic areas and geographies.

Viatris' 2023 Sustainability Report highlights significant progress in combatting infectious diseases like HIV, TB, malaria, and hepatitis. Viatris has expanded access to high-quality HIV/AIDS treatment, including self-testing diagnostics, pediatric therapies, and innovative formulations. In 2023, Viatris developed a dual oral pill for HIV and birth control with the Bill and Melinda Gates Foundation, targeting WHO approval by end-2024. The company also partnered with DNDi for slow-release flucytosine to treat cryptococcal meningitis.

Viatris supports local ARV manufacturing and engages in licensing agreements with organizations like Gilead and Viiv Healthcare. Over 32% of people on HIV treatment globally use Viatris products. In India, Viatris launched a single pill HIV treatment reaching 4,000 patients in six months. The company offers more than 700 infectious disease product registrations across LMICs.

In the fight against TB, Viatris introduced pretomanid for multidrug-resistant strains, approved in 57 countries. Efforts also extend to hepatitis B and C, with notable initiatives in the Philippines, Myanmar, and Bulgaria. Viatris' partnerships and innovative solutions aim to meet its goal of providing ARV therapy to 30 million patients by 2025.

Viatris Inc. (NASDAQ: VTRS) and its subsidiaries have launched cash tender offers for certain outstanding notes. The offers include:

• Any and all of the 1.650% Senior Notes due 2025 issued by Viatris
• Any and all of the 2.125% Senior Notes due 2025 issued by Mylan
• Up to $450 million aggregate principal amount of the 3.950% Senior Notes due 2026 issued by Utah Acquisition Sub Inc.

The Any and All Tender Offers expire on September 10, 2024, while the Maximum Tender Offer expires on October 2, 2024. Early tender payments are available for the Maximum Tender Offer Notes. The Total Consideration for each offer will be determined based on fixed spreads plus applicable yields. The offers are subject to various conditions and may be amended, extended, or terminated at the Offerors' discretion.

Viatris Inc. (NASDAQ: VTRS) presented results from a Phase 2 study of cenerimod for treating moderate to severe systemic lupus erythematosus (SLE) in Japanese patients at the 26th Asia-Pacific League of Associations for Rheumatology Annual Congress. The study, involving 17 patients, evaluated 2 mg and 4 mg doses of cenerimod, a selective S1P1 receptor modulator.

Key findings include:

• Both doses were considered safe and well-tolerated
• Expected decrease in lymphocyte counts, reversible upon treatment discontinuation
• Clinically meaningful improvement in disease activity, measured by mSLEDAI-2K
• Results consistent with the global Phase 2 CARE study

The presentation highlighted cenerimod's potential as a treatment for SLE, showcasing Viatris' commitment to addressing the needs of the SLE community.

Viatris reported Q2 2024 revenues of $3.8 billion, with a 2% operational growth on a divestiture-adjusted basis. New product revenues reached $210 million, driven by Breyna™ and lisdexamfetamine. Despite strong growth, the company reported a GAAP net loss of $326 million and a GAAP EPS loss of $0.27. However, adjusted EBITDA grew by 2% to $1.2 billion and adjusted EPS increased by 3% to $0.69 per share.

Viatris raised its full-year new product revenues guidance to $500-$600 million and expects a 2% operational growth. The company completed its divestitures and focuses on its diversified base business, financial strength, and innovative portfolio for future growth.

GAAP net cash from operations was $379 million, and free cash flow, excluding divestiture costs, was $426 million. Viatris also reduced its debt by $800 million.